- Trials with a EudraCT protocol (85)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
85 result(s) found for: Cell stress.
Displaying page 3 of 5.
EudraCT Number: 2014-001936-12 | Sponsor Protocol Number: MD2014.01 | Start Date*: 2019-02-11 | ||||||||||||||||
Sponsor Name:Sanquin Plasma Products BV | ||||||||||||||||||
Full Title: Efficacy and Safety of human apotransferrin in patients with β-thalassemia | ||||||||||||||||||
Medical condition: Beta thalassemia intermedia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-017872-26 | Sponsor Protocol Number: 1147/09 | Start Date*: 2010-02-22 | |||||||||||
Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI | |||||||||||||
Full Title: Role and pharmacological modulation of lug inflammation in chronic obstructive pulmonary disease (COPD) | |||||||||||||
Medical condition: chronic obstructive pulmonary disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-004571-73 | Sponsor Protocol Number: SOCOGAMI | Start Date*: 2017-12-15 |
Sponsor Name:Karolinska Institutet, Stockholm, Sweden [...] | ||
Full Title: SOdium-glucose CO-transporter inhibition in patients with newly detected Glucose Abnormalities post Myocardial Infarction (SOCOGAMI) | ||
Medical condition: Patients with acute coronary syndromes (myocardial infarction or unstable angina pectoris) with newly detected glucose perturbations (impaired glucose tolerance or type 2 diabetes) | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2022-003009-31 | Sponsor Protocol Number: HH007 | Start Date*: 2022-12-23 | |||||||||||
Sponsor Name:Zealand University Hospital, dept. of Haematology | |||||||||||||
Full Title: Atorvastatin for patients with Philadelphia-negative chronic myeloproliferative neoplasms - Essential thrombocythemia, polycythemia vera and prefibrotic myelofibrosis | |||||||||||||
Medical condition: Essential thrombocythemia, Polycythemia vera, prefibrotic myelofibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-001640-56 | Sponsor Protocol Number: PI12/01866 | Start Date*: 2014-01-31 | |||||||||||
Sponsor Name:Fundación Para la Investigación Biomédica de Córdoba | |||||||||||||
Full Title: Crossover clinical trial, randomized, double blind, placebo controlled trial. Modulation of cellular mediators and repair endothelial damage in patients with chronic renal disease through inhibitio... | |||||||||||||
Medical condition: Patients with chronic kidney disease and asymptomatic hyperuricemia on the balance of mechanisms of vascular injury and repair. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002979-34 | Sponsor Protocol Number: LTFU-ABO-102 | Start Date*: 2020-05-18 | |||||||||||
Sponsor Name:Abeona Therapeutics Inc | |||||||||||||
Full Title: A Long-term Follow-up Study of Patients with MPS IIIA from Gene Therapy Clinical Trials Involving the Administration of ABO-102 (scAAV9.U1a.hSGSH) | |||||||||||||
Medical condition: MPS IIIA is a devastating lysosomal storage disease, caused by a Nsulfoglucosamine sulfohydrolase gene defect. Infants with MPS IIIA appear normal at birth, but the disease is relentlessly progress... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002085-31 | Sponsor Protocol Number: RAD-ON02 | Start Date*: 2017-11-14 |
Sponsor Name:Kurort Forschungsverein Bad Steben e.V. | ||
Full Title: Determining the immunological and pain reducing effects of serial radon balneology in patients with musculoskeletal disorders. | ||
Medical condition: Chronic degenerative spine and/or joint disorders with pain perception of at least 1 year and pain intensity on visual analogue scale ≥4 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2016-003902-14 | Sponsor Protocol Number: 16-118 | Start Date*: 2017-07-06 |
Sponsor Name:RWTH Aachen University, represented by the Clinical Trial Center (CTC-A) | ||
Full Title: Intravenous Fish Oil based Lipid Emulsion as Pharmaconutrient Strategy in High-Risk Cardiac Surgery Patients: a Phase II Dosing Study | ||
Medical condition: Given the recently meta-analyzed data from previous RCTs about fish oil , we hypothesize that the provision of intravenous (i.v.) FO (0.20 g/kg and 0.50 g/kg) to cardiac surgery patients may reduc... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-005961-16 | Sponsor Protocol Number: QVID-001 | Start Date*: 2021-02-05 | |||||||||||
Sponsor Name:Lars Jørgen Østergaard | |||||||||||||
Full Title: Coenzyme Q10 as treatment for Long Term COVID-19 (The QVID study) | |||||||||||||
Medical condition: Long Term COVID-19 illness | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002326-36 | Sponsor Protocol Number: 2016-858 | Start Date*: 2016-11-09 | ||||||||||||||||
Sponsor Name:Region Hovedstadens psykiatriske hospital | ||||||||||||||||||
Full Title: Effects of erythropoietin (EPO) on cognitive side-effects of electroconvulsive therapy (ECT) (EPO-T) | ||||||||||||||||||
Medical condition: Unipolar/bipolar depression | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2005-005791-32 | Sponsor Protocol Number: HF0220/003 | Start Date*: 2006-04-24 | |||||||||||
Sponsor Name:Hunter-Fleming Ltd | |||||||||||||
Full Title: Chemical Safety/Tolerability of HF0220 and its Effect on Biochemical Markers Relevant to Patients with a Diagnosis of Mild to Moderate Alzheimer's Disease. | |||||||||||||
Medical condition: HF0220 experimentally appears to exert its potential beneficial effects within the CNS and possibly other tissues by attenuating the adverse effects of oxidative stress. It is believed that this me... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) SE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001749-42 | Sponsor Protocol Number: 484/12 | Start Date*: 2012-08-07 | |||||||||||
Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI | |||||||||||||
Full Title: Effects of treatment and withdrawal with inhaled beclomethasone/formoterol on lung inflammation in COPD. | |||||||||||||
Medical condition: Chronic obstructive pulmonary disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003542-17 | Sponsor Protocol Number: FISM_IRON-MDS | Start Date*: 2019-05-06 | |||||||||||
Sponsor Name:FONDAZIONE ITALIANA SINDROMI MIELODISPLASTICHE ETS | |||||||||||||
Full Title: Early and low dose Deferasirox (3.5 mg/kg FCT) to suppress NTBI and LPI as early intervention to prevent tissue iron overload in lower risk MDS | |||||||||||||
Medical condition: Adult patients with low risk MDS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-006109-26 | Sponsor Protocol Number: LANT_001 | Start Date*: 2008-12-10 | |||||||||||
Sponsor Name:Institut für Klinische Forschung und Entwicklung (ikfe) GmbH | |||||||||||||
Full Title: Impact of Insulin Glargine compared to Insulin Detemir in combination with Metformin (BOT) on prandial beta cell function and overall metabolic control in type 2 diabetic patients with insufficient... | |||||||||||||
Medical condition: Diabetes mellitus Type 2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-005747-29 | Sponsor Protocol Number: BP20843 | Start Date*: 2007-03-14 | ||||||||||||||||
Sponsor Name:F. HOFFMANN-LA ROCHE LTD | ||||||||||||||||||
Full Title: Evaluation of the relationship between HDL quantity and HDL functionality in patients treated with HDL-C raising drugs | ||||||||||||||||||
Medical condition: Primary hypercholesterolemia or mixed dyslipidemia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Completed) IT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003299-15 | Sponsor Protocol Number: METFORAGING | Start Date*: 2021-10-19 |
Sponsor Name:Fundación para la Investigación Biomédica del Hospital La Paz | ||
Full Title: A double blinded, phase II, placebo controlled, single center randomized clinical trial to evaluate metformin compared with placebo for reversal of accelerated biological aging in persons living wi... | ||
Medical condition: Patients with HIV and accelerated biological aging | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2017-004318-25 | Sponsor Protocol Number: NL63681.029.18 | Start Date*: 2019-04-16 | |||||||||||
Sponsor Name:VU University Medical Center | |||||||||||||
Full Title: Early high-dose vitamin C in post-cardiac arrest syndrome. | |||||||||||||
Medical condition: Patients admitted to the Intensive Care after out-of-hospital cardiac arrest with return of spontaneous circulation, ventricular fibrillation or ventricular tachycardia as first registered cardiac ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-000885-39 | Sponsor Protocol Number: 02289 | Start Date*: 2021-01-12 | |||||||||||
Sponsor Name:Universitätsmedizin Göttingen | |||||||||||||
Full Title: Safety and Efficacy of Induced Pluripotent Stem Cell-derived Engineered Human Myocardium as Biological Ventricular Assist Tissue in Terminal Heart Failure | |||||||||||||
Medical condition: Heart Failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004434-41 | Sponsor Protocol Number: 70917 | Start Date*: 2020-04-16 | |||||||||||
Sponsor Name:Flemming Pociot | |||||||||||||
Full Title: Fenofibrate as an Early Treatment Option in Type 1 Diabetes: A randomized, double-blind, placebo-controlled, trial to evaluate antidiabetic effects of Fenofibrate in patient with newly onset type 1... | |||||||||||||
Medical condition: Newly onset Type 1 Diabetes, with first insulin injection maximum six weeks prior inclusion in this trial | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002217-35 | Sponsor Protocol Number: AG348-C-010 | Start Date*: 2018-11-20 | |||||||||||
Sponsor Name:Agios Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 2, Open-Label, Multicenter Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adult Subjects With Non-Transfusion-Dependent Thalassemia | |||||||||||||
Medical condition: Non-Transfusion-Dependent Thalassemia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
